Generex unveils strategic development plan, including Antigen Express spin-out

1 April 2011

USA-based Generex Biotechnology (OTC Bulletin Board: GNBT) unveiled management's strategic development plan for the company's future growth at a press conference this week which included a spin out and two senior management appointments.

Chairman John Barratt said that the board has appointed Mark Fletcher as the company's president and chief executive on a go-forward basis, saying: "The Board has been entirely satisfied with Mr Fletcher's work in that role on an interim basis over the course of a challenging transition period these past six months."

Mr Barratt also noted that the board has appointed David Brusegard as chief operating officer and current vice president of finance, Stephen Fellows, as acting chief financial officer to complete its new management team. Gerald Bernstein will continue as the company's VP for medical Affairs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK